Cancer News and Research

Latest Cancer News and Research

New drug testing technique is safe and effective

A new study from the Swedish medical university Karolinska Institutet presents a new technique that makes drug testing possible through exhaled air for the first time.

21 May 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Abraxis BioScience, Inc., a fully integrated biotechnology company, previously announced it will be presenting more than 30 studies, including new clinical data evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel (ABRAXANE for Injectable suspension; paclitaxel protein albumin-bound particles for injectable suspension) for the treatment of pancreatic cancer at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Living wills do not represent patients’ treatment preferences in end-of-life scenarios

Living wills often do not represent a patient's actual treatment preferences when faced with real end-of-life circumstances and should be redesigned to guide more realistic advance decision-making, according to a study published in Journal of Palliative Medicine, a peer-reviewed journal from Mary Ann Liebert, Inc.

21 May 2010

Researchers discover key gene that promotes development of common kidney cancer

Researchers at Mayo Clinic's campus in Florida have discovered a key gene that, when turned off, promotes the development of common kidney cancer. Their findings suggest that a combination of agents now being tested in other cancers may turn the gene back on, providing a much-needed therapy for the difficult-to-treat cancer.

21 May 2010

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Nektar Therapeutics today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract Session of the Gynecologic Cancer Track during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

21 May 2010

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has announced further positive data on the first forty subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.

21 May 2010

Cord Blood America reviews first quarter results

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that its co-founder and CEO, Matthew Schissler, reviewed first quarter results and progress in an interview with analyst Francis Gaskins.

21 May 2010

ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma at ASCO meeting

ZIOPHARM Oncology, Inc. announced today that Dr. Claire Verschraegen of the University of New Mexico, Albuquerque, lead author of the abstract on the palifosfamide study entitled, "A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO)", will present in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 7th at 2:15 pm in the Vista Room (location S 406).

21 May 2010

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

Sorrento Therapeutics, Inc. today announced that it has received an Advanced Technology Small Business Technology Transfer Research grant from the National Institute of Allergy and Infectious Diseases. The peer-reviewed grant was awarded to support the Company's program to generate and develop novel antibody therapeutics and vaccines to combat Staphylococcus aureus infections, including methicillin-resistant S. aureus, by disrupting quorum sensing, a bacterial communication process essential to virulence.

21 May 2010

'Teachable moments' can reduce cancer risk in children of parents with mutations in tumor suppressor genes

Parents found to be carriers of a mutated form of the tumor suppressor genes known as BRCA1 and BRCA2 do not always share these test results with their children, but they may choose to discuss related information important to their own health with them. That is the result of a study conducted by an investigator at The Cancer Institute of New Jersey (CINJ) and colleagues, whose findings suggest that those parents are using the discovery of their mutation status as an opportunity for a "teachable moment" in educating their offspring about cancer risk reduction.

21 May 2010

Routine cessation of clopidogrel in patients before colonoscopy polypectomy not necessary: Researchers

Researchers at the Syracuse Veterans Affairs Medical Center in New York examined postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel and found that the postpolypectomy bleeding rate is significantly higher in patients undergoing polypectomy while taking clopidogrel and concomitant aspirin/nonsteroidal anti-inflammatory drugs, but that the risk is small and the outcome is favorable.

21 May 2010

Research team investigates infants with suspected GERD using combined pH/MII monitoring

Gastroesophageal reflux, defined as passage of gastric contents into the esophagus is a normal process that occurs in healthy infants, children and adults. When GER causes troublesome symptoms and/or complications it is referred to as gastroesophageal reflux disease. During infancy, GER is common and can manifest with specific symptoms as vomiting and non-specific symptoms as irritability and cough. Association of non-specific symptoms with GER is a main problem in the diagnosis of GERD.

21 May 2010

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.

21 May 2010

eGFR as valuable as Ccr as an indicator of preoperative renal function in gastric cancer patients: Study

The creatinine clearance (Ccr) test has been used as a gold standard for evaluation of preoperative renal function in patients with gastric cancer. However, it is known that Ccr is not strictly equivalent to glomerular filtration rate (GFR). It has been accepted that estimated GFR (eGFR) is equal to measured GFR in chronic kidney disease. However, there have been no studies regarding the reliability of eGFR as a preoperative renal function test in gastric cancer patients.

21 May 2010

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine -targeting antibody bavituximab for the treatment of solid tumors.

21 May 2010

German states may face healthcare crisis: Study

Within the next ten years, there will be deficiencies in healthcare provision in parts of Mecklenburg-West Pomerania. This is the conclusion reached by Ulrike Siewert of Greifswald University and her coauthors in the current edition of Deutsches -rzteblatt International.

21 May 2010

Vitamin D plays much wider role in people's life

Vitamin D is the sunshine vitamin - we make it when our skin is exposed to UV rays. In a perfect world everyone would eat fresh, organic foods, get outside, and enjoy a little sunshine all year round. But with today's busy lifestyles and concerns about skin cancer many people are vitamin D deficient and don't know it.

21 May 2010

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced data from the Phase III PRIMA study.

21 May 2010

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Results of two Phase II trials evaluating ALIMTA (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill., on June 6, 2010.

21 May 2010

Cancer News and Research

Latest Cancer News and Research

New drug testing technique is safe and effective

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Living wills do not represent patients’ treatment preferences in end-of-life scenarios

Researchers discover key gene that promotes development of common kidney cancer

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Provectus to present further positive data from PV-10 Phase 2 clinical trial for metastatic melanoma at ASCO

Cord Blood America reviews first quarter results

ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma at ASCO meeting

Sorrento Therapeutics receives STTR grant to develop antibody therapeutics to combat MRSA

'Teachable moments' can reduce cancer risk in children of parents with mutations in tumor suppressor genes

Routine cessation of clopidogrel in patients before colonoscopy polypectomy not necessary: Researchers

Research team investigates infants with suspected GERD using combined pH/MII monitoring

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

eGFR as valuable as Ccr as an indicator of preoperative renal function in gastric cancer patients: Study

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

German states may face healthcare crisis: Study

Vitamin D plays much wider role in people's life

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Newsletters you may be interested in